Colosseum has released Copilot v2, an upgraded AI tool that enhances Solana project development by integrating data from 8,286 hackathon projects across five events, including the recent Frontier Hackathon. The tool offers trend analysis, tags tools used in past projects, and provides personalized recommendations based on a developer's tech stack. This upgrade helps developers better understand project trends and select relevant tools, supporting more efficient and informed building on Solana. Access to Copilot v2 is free with a Colosseum account, aiming to facilitate hackathon participation and developer support without any associated token launch.
Colosseum's upgrade to its AI Copilot tool for Solana project development provides useful context for digital asset markets. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Oct 02, 2026 03:52 WIB: out of 50 priced cryptocurrencies, 32 rose and 17 fell. Notable movers include SAND at Rp797 with a 1-day change of +2.92% and a typical hold time of 123 days, THETA at Rp3.930 down 2.92% with 77 days typical hold, and UNI at Rp163.383 up 2.91% with a 65-day hold time.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
